Wet Wrap Dressings for Atopic Dermatitis

Topical ______ are effective to decrease inflammation and pruritus in acute and chronic forms of AD.

Wet wrap dressings have been shown to reduce ______ and pruritus by serving as a barrier to trauma, cooling the skin and improving penetration of topical therapies.

For mild disease activity, small amounts of ______ in combination with liberal emollient use may be sufficient without producing adverse effects.

Wet wrap dressings involve wrapping damp ______ gauze over the affected skin, underneath a layer of dry gauze, usually overnight.

The lowest effective ______ of TCS should be used to avoid irreversible atrophy of the skin.

Long-term control of AD can be maintained with twice-weekly use of the ______ or Topical Calcineurin Inhibitors (TCI) to areas previously affected even if they appear normal.

Epidermal barrier failure is thought to be a main driving force behind subsequent proinflammatory ______ in AD

Moisturizers are a daily part of skin care in atopic dermatitis and patients often use a variety of products based on ______, skin type, season, and disease state

Regular ______ use has been demonstrated to have a steroid-sparing benefit in managing atopic dermatitis

Therapy with systemic ______ and anxiolytics are effective through their soporific effects used in the evening

Ceramides, hyaluronic acid, dimethicone, licorice extract (glycyrrhetinic acid), and ______ are ingredients in prescription “barrier repair creams”

Relieving the ______ of AD is crucial in preventing the itch-scratching cycle of this disorder

Calcineurin inhibitors prevent T-cell ______, inhibit inflammatory cytokine release and down-regulate high affinity IgE receptor expression on Langerhans cells.

Topical ______ (ProtopicTM) and pimecrolimus (ElidelTM) have been approved for the treatment of AD in the United States and Europe.

The most common adverse side effect of crisaborole ointment (EucrisaTM) consists of ______ at the site of application.

Crisaborole ointment (EucrisaTM) came on the market at the end of 2016 for children over 2 years of age and adults with ______ to moderate AD.

Crisaborole ointment (EucrisaTM) works by inhibiting ______-4 (PDE-4), preventing breakdown of cyclic AMP (cAMP).

Crisaborole ointment (EucrisaTM) ultimately leads to an increase in ______ cytokines.